IDeA Reauthorization Act of 2025 Purpose A bill to improve the Institutional Development Award program of the National Institutes of Health.

CHICAGO, July 01, 2025--MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress ...

CHICAGO-- (BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

In order to expand the dialogue on the directions of pharmaceutical assistance in the Unified Health System (SUS), the State Health Department of Pará (Sespa) participates in the III Pará Congress on ...

Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY (fremanezumab) is effective in ...